Cipla shares slide 5% after drug major's Q3 net profit drops 57% YoY

Cipla shares fell as much as 5% on Friday (January 23), hitting an intraday low of Rs 1,303 on the NSE, after the pharma major reported a 57% year-on-year decline in consolidated net profit to Rs 676 crore. Revenue from operations for the period remained flat year-on-year at Rs 7,074 crore.

The selling pressure occurred amid significant volumes, with nearly 52 lakh shares changing hands on the NSE around 2:45 pm. The sentiments also worsened because of steep cuts in the broader markets.

Umang Vohra, MD and Global CEO, Cipla, said, “Our upcoming launches are expected to cushion gRevlimid revenue decline and provide long-term growth.” The earnings were hit by a drop in gRevlimid sales, which dragged the overall North America business.


Read more: Cipla Q3 Results: Net profit plunges 57% YoY to Rs 676 crore

EBITDA for the quarter dropped 37% YoY to Rs 1,255 crore, while margins declined to 17.7%.

Segment-wise, within the One India business, branded prescriptions posted double-digit growth of 10% year-on-year. Key therapies such as Respiratory, Urology, Cardiac and anti-diabetes recorded strong double-digit market growth, helping improve the overall chronic mix to 62.3%.

In trade generics, performance was supported by steady execution across distribution, new product launches and technology-led interventions. The business launched eight new products in Q3FY26, including its entry into the sexual wellness segment to expand therapy coverage.

The Nifty stock has been a market laggards, declining 9% in the past 12 months when Nifty's gains stand at over 8%. The stock is currently trading below its 50-day and 200-day simple moving averages (SMAs) of Rs 1,492.7 and Rs 1,513.4, respectively, according to Trendlyne data.

Going ahead, Cipla, in a statement, said the focus will be on growing our key markets, further building flagship brands, investing in the future pipeline, as well as focusing on resolutions on the regulatory front.

(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)